Convergen
Suzhou
About Convergen
Convergen develops TrimTAC, a targeted protein degradation platform for treating neurodegenerative diseases and other conditions driven by protein aggregates
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $10.0M
- Funding stage: Seed
- Last round: Seed (Dec 2025)
- Website: convergenbio.com
Industries & Categories
Biotechnology, Manufacturing, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/convergen-95481 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.